PRMT5 and glioblastoma: For instance, MTAP-deficient tumors have shown improved treatment outcomes in various cancers such as pancreatic cancer and glioblastoma by utilizing PRMT5 as a synthetic lethal target (Huang et al., 2020; Alhalabi et al., 2022).